TICKERNERD
Menu
YCBDYCBDHealthcare · Drug Manufacturers - Specialty & Generic

YCBD Stock Forecast: cbdMD, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.41
−0.25% on the day

The 1 Wall Street analysts covering cbdMD, Inc. hold a median 12-month price target of $2 — +391.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 7 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.6M
Ticker Nerd rank
34 / 100
Median analyst target
$2.00
Analysts covering
1
Revenue$5.6M+20.6% y/y
Operating income−$1.1M
Net income−$1.1M
Free cash flow−$460K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.2%
1M
−14.5%
YTD
−69.9%
1Y
−72.5%
From 52W high
−82.1%
From 52W low
0.0%
$0.41
$2.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

YCBD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores cbdMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Quality
71
Volatility
67
Growth
48
Momentum
42
Revisions
33
Value
32
Accruals
30
Issuance
8

Size (96): Smaller than most of the companies we track.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

YCBD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YCBD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26YCBDHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $2.00Median $2.00High $2.00

The green dot is the last close — the median target sits +391.4% from it.

Recent analyst actionsNewest first

Of the 11 most recent actions, 4 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Aug 2026Maxim GroupDowngradeHold—
20 Aug 2025Maxim GroupMaintainsBuy—
22 May 2025Maxim GroupMaintainsBuy—
5 Oct 2023Maxim GroupInitiatesBuy—
18 June 2021Cantor FitzgeraldReinstatesNeutral$4.10 → $3.25
3 Feb 2021Cantor FitzgeraldReiteratesNeutral$4.30 → $4.10
29 Jan 2021Cantor FitzgeraldMaintainsNeutral$3.60 → $4.30
9 Sept 2020BenchmarkMaintainsSpeculative Buy$3.00 → $4.00
13 Aug 2020Cantor FitzgeraldMaintainsNeutral$1.80 → $3.60
18 May 2020Cantor FitzgeraldMaintainsNeutral$1.20 → $1.80
19 Dec 2019BenchmarkMaintainsSpeculative Buy$9.00 → $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YCBD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

YCBD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, cbdMD, Inc. returned −72.5% against +17.4% for the S&P 500, dividends included.

YCBD vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26YCBDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

YCBD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

cbdMD, Inc. (YCBD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.8×

Cheaper than 70% of US stocks

Price / sales
0.2×

Cheaper than 91% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
−2.5×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
20.6%

Higher than 70% of US stocks

Earnings growth (YoY)
20.6%

Higher than 59% of US stocks

Gross margin
54.7%

Higher than 67% of US stocks

Operating margin
−20.4%

Higher than 21% of US stocks

Net margin
−13.8%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−40.3%

Higher than 24% of US stocks

Return on assets
−15.8%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

cbdMD, Inc. (YCBD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • cbdMD, Inc. has a market value of $4.6M and an enterprise value of $4.7M.

  • Revenue in the twelve months to 30 June 2026: $20.9M. The latest quarter grew 20.6% year on year.

  • Net income over the same four quarters: −$2.9M, a −13.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.4M.

  • Shares outstanding: 11.1M.

  • Trailing P/E: 1.8×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • cbdMD, Inc. employs 42 people — $498K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

YCBD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
YCBDcbdMD, Inc.$4.6M
34
SXTCChina Sxt Pharmaceuticals, Inc.$3.7M
9
SNOASonoma Pharmaceuticals, Inc.$5.8M
35
GELSGelteq Ltd.$6.0M
11
IMCCIM Cannabis Corp.$3.1M
20
SBFMSunshine Biopharma, Inc.$3.0M
61
INMInMed Pharmaceuticals, Inc.$7.3M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own cbdMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest YCBD news & analysis

Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation

PRNewsWire · 24 Sept 2026neutral

Reserveage, part of the Twinlab family of brands, launched Longev+, a new supplement available exclusively at The Vitamin Shoppe, combining amino acids, HMB, creatine and resveratrol to bring muscle health and everyday performance into the healthy aging routine. The launch comes as Twinlab brands await a proposed acquisition by cbdMD.

Why it matters — cbdMD watchers would care because this Reserveage product launch under the Twinlab brand family relates to the portfolio involved in cbdMD's proposed acquisition.

cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness

PRNewsWire · 2 Sept 2026positive

cbdMD announced it has entered a definitive agreement to acquire Twinlab Brands, adding iconic supplement brands across legacy supplements, sports nutrition, women's beauty, weight loss, and longevity wellness to its multi-brand consumer wellness platform. The acquisition is expected to increase cbdMD's revenues to approximately $30 million.

Why it matters — This acquisition expands cbdMD beyond CBD into a broader multi-brand wellness platform and is expected to roughly double its revenue, making it a significant strategic growth development for shareholders.

cbdMD, Inc. (YCBD) Q3 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of cbdMD, Inc.'s (YCBD) Q3 2026 earnings call. The item consists solely of the earnings call transcript headline with no accompanying analysis or commentary.

Why it matters — A YCBD watcher would care because the earnings call transcript is the primary record of the company's latest quarterly results and management commentary.

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

PRNewsWire · 13 Aug 2026positive

cbdMD, Inc. announced financial results for its third fiscal quarter of 2026, ended June 30, 2026, reporting 20% year-over-year revenue growth. The results included accelerating momentum for its Oasis hemp-derived THC beverage brand and a full quarter of contribution from Bluebird Botanicals, with the company also noting advancing federal hemp legislation.

Why it matters — The reported 20% revenue growth, along with progress on federal hemp legislation, signals strengthening positioning for YCBD as it prepares to compete under pending federal regulations.

cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results

PRNewsWire · 10 Aug 2026neutral

cbdMD, Inc. (NYSE American: YCBD) announced it will host a conference call at 4:20 p.m. to discuss its third quarter results for the period ending June 30, 2026. The announcement was made via PRNewswire on Aug. 10, 2026.

Why it matters — YCBD watchers would care because the conference call will provide insight into the company's third quarter financial performance.

FAQ

Frequently asked questions about YCBD stock

What is the YCBD stock price forecast for 2026-2027?

The 1 Wall Street analysts covering cbdMD, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is YCBD stock a buy right now?

Of the 1 analysts covering cbdMD, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks cbdMD, Inc. 34 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank YCBD?

As at 7 Oct 2026, cbdMD, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will YCBD stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +391.4% from the last close, and Ticker Nerd's factor model ranks cbdMD, Inc. 34 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the YCBD stock forecast for 2030?

No analyst covering cbdMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YCBD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has YCBD stock performed over the past year?

cbdMD, Inc. returned -72.5% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does cbdMD, Inc. do?

cbdMD Inc. is a consumer wellness company focused on hemp-derived cannabinoid products and related functional brands.

What is the latest news on YCBD?

The most recent item we track (PRNewsWire, 24 Sept 2026): "Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation". Reserveage, part of the Twinlab family of brands, launched Longev+, a new supplement available exclusively at The Vitamin Shoppe, combining amino acids, HMB, creatine and resveratrol to bring muscle health and everyday performance into the healthy aging routine. The launch comes as Twinlab brands await a proposed acquisition by cbdMD.

Company

About cbdMD, Inc.

cbdMD Inc. is a consumer wellness company focused on hemp-derived cannabinoid products and related functional brands. cbdMD offers a broad range of products for human and pet use, including CBD tinctures, gummies, topicals, capsules, softgels, oils, bath products, drink mixes, sleep and calming aids, and hemp-derived Delta-9 THC formulations. Its portfolio includes the cbdMD, Paw CBD, hempMD, cbdMD Botanicals, and ATRx brands, serving customers through e-commerce, wholesale partners, and brick-and-mortar retail channels. The company’s products are positioned across wellness categories such as recovery, mobility, mood, discomfort, cognitive support, and stress management. Based in Charlotte, North Carolina, cbdMD Inc. operates as a specialized brand owner and distributor within the evolving hemp and natural supplements market.

CEO Mr. T. Ronan Kennedy · 42 employees · United States · https://www.cbdmd.com